Hasil Pencarian (1)
small molecule | CAS: 1354690-24-6
Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase ? (PI3K?). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).[L45758] APDS is a primary immuno…
Kategori:
Adjuvants, ImmunologicAntineoplastic and Immunomodulating AgentsBCRP/ABCG2 Inhibitors
+14
Target Protein:
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Waktu ParuhThe effective half-…
Vol. DistribusiThe systemic decay …
KlirensIn one study, healt…
Genetik
-